174 related articles for article (PubMed ID: 27122208)
41. Benefit of consolidative radiation therapy for primary bone diffuse large B-cell lymphoma.
Tao R; Allen PK; Rodriguez A; Shihadeh F; Pinnix CC; Arzu I; Reed VK; Oki Y; Westin JR; Fayad LE; Medeiros LJ; Dabaja B
Int J Radiat Oncol Biol Phys; 2015 May; 92(1):122-9. PubMed ID: 25754633
[TBL] [Abstract][Full Text] [Related]
42. [Expression of Bcl-2 gene and its effect on prognosis of patients with primary gastrointestinal diffuse large B-cell lymphoma].
Zhang L; Zhao H; Li X; Xia B; Zheng H; Li H; Sun B; Zhang Y
Zhonghua Zhong Liu Za Zhi; 2014 Oct; 36(10):755-60. PubMed ID: 25567306
[TBL] [Abstract][Full Text] [Related]
43. Presence of a high-grade component in gastric mucosa-associated lymphoid tissue (MALT) lymphoma is not associated with an adverse prognosis.
Ang MK; Hee SW; Quek R; Yap SP; Loong S; Tan L; Tao M; Lim ST
Ann Hematol; 2009 May; 88(5):417-24. PubMed ID: 18777110
[TBL] [Abstract][Full Text] [Related]
44. Visceral adipose tissue is prognostic for survival of diffuse large B cell lymphoma treated with frontline R-CHOP.
Shin DY; Kim A; Byun BH; Moon H; Kim S; Ko YJ; Kim MJ; Lee HR; Kang HJ; Na II; Park S; Lee SS; Yang SH
Ann Hematol; 2016 Feb; 95(3):409-16. PubMed ID: 26658607
[TBL] [Abstract][Full Text] [Related]
45. [Analysis of the Clinicopathological Characteristics, Treatment and Prognosis of Unclassifiable B-Cell Lymphoma Intermediated between DLCBL and BL].
Liu DL; Wang B; Zhu YD; Yan F
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Apr; 26(2):443-448. PubMed ID: 29665913
[TBL] [Abstract][Full Text] [Related]
46. High expression of REV7 is an independent prognostic indicator in patients with diffuse large B-cell lymphoma treated with rituximab.
Okina S; Yanagisawa N; Yokoyama M; Sakurai Y; Numata Y; Umezawa A; Higashihara M; Murakumo Y
Int J Hematol; 2015 Dec; 102(6):662-9. PubMed ID: 26449786
[TBL] [Abstract][Full Text] [Related]
47. High-dose therapy and autologous stem cell transplantation in patients with diffuse large B-cell lymphoma in first complete or partial remission.
Papajik T; Raida L; Faber E; Vondrakova J; Prochazka V; Kubova Z; Skoumalova I; Jarosova M; M LK; Paucek B; Myslivecek M; Neoral C; Oral I; Jarkovsky J; Dusek L; Indrak K
Neoplasma; 2008; 55(3):215-21. PubMed ID: 18348654
[TBL] [Abstract][Full Text] [Related]
48. The highest prognostic impact of LDH among International Prognostic Indices (IPIs): an explorative study of five IPI factors among patients with DLBCL in the era of rituximab.
Park JH; Yoon DH; Kim DY; Kim S; Seo S; Jeong Y; Lee SW; Park CS; Huh J; Suh C
Ann Hematol; 2014 Oct; 93(10):1755-64. PubMed ID: 25027115
[TBL] [Abstract][Full Text] [Related]
49. Total lesion glycolysis in positron emission tomography is a better predictor of outcome than the International Prognostic Index for patients with diffuse large B cell lymphoma.
Kim TM; Paeng JC; Chun IK; Keam B; Jeon YK; Lee SH; Kim DW; Lee DS; Kim CW; Chung JK; Kim IH; Heo DS
Cancer; 2013 Mar; 119(6):1195-202. PubMed ID: 23212736
[TBL] [Abstract][Full Text] [Related]
50. [Analysis of Clinical Feature and Treatment Outcome of Patients with Renal Diffuse Large B Cell Lymphoma].
Yang P; Jing HM; Zhao W; Hu K; Wan W; Tian L; Ke XY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Dec; 24(6):1737-1742. PubMed ID: 28024486
[TBL] [Abstract][Full Text] [Related]
51. [Clinical characteristics and treatment strategies for early-stage primary gastric diffuse large B-cell lymphoma].
Qin Y; Liu P; Yang JL; Jin J; He XH; Wang WH; Fang H; Zhou SY; Zhou LQ; Song YW; Shi YK
Zhonghua Yi Xue Za Zhi; 2018 Jun; 98(24):1945-1950. PubMed ID: 29996288
[No Abstract] [Full Text] [Related]
52. The therapeutic effect of rituximab on CD5-positive and CD5-negative diffuse large B-cell lymphoma.
Hyo R; Tomita N; Takeuchi K; Aoshima T; Fujita A; Kuwabara H; Hashimoto C; Takemura S; Taguchi J; Sakai R; Fujita H; Fujisawa S; Ogawa K; Motomura S; Suzuki R; Ishigatsubo Y
Hematol Oncol; 2010 Mar; 28(1):27-32. PubMed ID: 19358143
[TBL] [Abstract][Full Text] [Related]
53. [Influence of transplantation and some clinical factors on prognosis of patients with diffuse large B-cell lymphoma].
Zhao SX; Han Y; Zhu Q; Wang Q; Zhang WJ; Chen XC; Sun AN; Jin ZM; Qiu HY; Tang XW; Fu ZZ; He GS; Miao M; Ma X; Wu DP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Jun; 21(3):623-7. PubMed ID: 23815910
[TBL] [Abstract][Full Text] [Related]
54. Ocular adnexal diffuse large B-cell lymphoma: a multicenter international study.
Munch-Petersen HD; Rasmussen PK; Coupland SE; Esmaeli B; Finger PT; Graue GF; Grossniklaus HE; Honavar SG; Khong JJ; McKelvie PA; Mulay K; Prause JU; Ralfkiaer E; Sjö LD; Sniegowski MC; Vemuganti GK; Heegaard S
JAMA Ophthalmol; 2015 Feb; 133(2):165-73. PubMed ID: 25393033
[TBL] [Abstract][Full Text] [Related]
55. Prognostic Value of Anemia and C-Reactive Protein Levels in Diffuse Large B-Cell Lymphoma.
Adams HJ; de Klerk JM; Fijnheer R; Heggelman BG; Dubois SV; Nievelstein RA; Kwee TC
Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):671-9. PubMed ID: 26361646
[TBL] [Abstract][Full Text] [Related]
56. Comparison of prognostic models for patients with diffuse large B-cell lymphoma in the rituximab era.
Huang YC; Liu CY; Lu HJ; Liu HT; Hung MH; Hong YC; Hsiao LT; Gau JP; Liu JH; Hsu HC; Chiou TJ; Chen PM; Tzeng CH; Yu YB
Ann Hematol; 2013 Nov; 92(11):1513-20. PubMed ID: 23775580
[TBL] [Abstract][Full Text] [Related]
57. Prognostic value of total lesion glycolysis of baseline 18F-fluorodeoxyglucose positron emission tomography/computed tomography in diffuse large B-cell lymphoma.
Zhou M; Chen Y; Huang H; Zhou X; Liu J; Huang G
Oncotarget; 2016 Dec; 7(50):83544-83553. PubMed ID: 27835875
[TBL] [Abstract][Full Text] [Related]
58. Clinicopathological prognostic factors of 24 patients with B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma.
Miyamoto K; Kobayashi Y; Maeshima AM; Taniguchi H; Nomoto J; Kitahara H; Fukuhara S; Munakata W; Maruyama D; Tobinai K
Int J Hematol; 2016 Jun; 103(6):693-702. PubMed ID: 27095041
[TBL] [Abstract][Full Text] [Related]
59. Statin use has negative clinical impact on non-germinal center in patients with diffuse large B cell lymphoma in rituximab era.
Song MK; Chung JS; Lee GW; Cho SH; Hong J; Shin DY; Shin HJ
Leuk Res; 2015 Feb; 39(2):211-5. PubMed ID: 25541029
[TBL] [Abstract][Full Text] [Related]
60. Cd20 Expression and Effects on Outcome of Relapsed/ Refractory Diffuse Large B Cell Lymphoma after Treatment with Rituximab.
Rasheed AA; Samad A; Raheem A; Hirani SI; Shabbir- Moosajee M
Asian Pac J Cancer Prev; 2018 Feb; 19(2):331-335. PubMed ID: 29479962
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
